Ovid Therapeutics, Inc. (OVID)
2.375
-0.10
(-3.85%)
USD |
NASDAQ |
Oct 22, 16:00
2.375
0.00 (0.00%)
After-Hours: 20:00
Ovid Therapeutics Net Income (Quarterly) : -15.01M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -15.01M |
| March 31, 2026 | -16.99M |
| December 31, 2025 | 9.664M |
| September 30, 2025 | -12.16M |
| June 30, 2025 | -4.684M |
| March 31, 2025 | -10.24M |
| December 31, 2024 | -9.253M |
| September 30, 2024 | -14.01M |
| June 30, 2024 | 8.521M |
| March 31, 2024 | -11.69M |
| December 31, 2023 | -15.32M |
| September 30, 2023 | -11.25M |
| June 30, 2023 | -12.41M |
| March 31, 2023 | -13.36M |
| December 31, 2022 | -11.50M |
| September 30, 2022 | -11.97M |
| June 30, 2022 | -14.59M |
| March 31, 2022 | -16.11M |
| December 31, 2021 | -25.15M |
| Date | Value |
|---|---|
| September 30, 2021 | -11.38M |
| June 30, 2021 | -15.79M |
| March 31, 2021 | 168.57M |
| December 31, 2020 | -22.03M |
| September 30, 2020 | -16.42M |
| June 30, 2020 | -22.55M |
| March 31, 2020 | -20.03M |
| December 31, 2019 | -16.97M |
| September 30, 2019 | -16.63M |
| June 30, 2019 | -13.06M |
| March 31, 2019 | -13.80M |
| December 31, 2018 | -12.90M |
| September 30, 2018 | -12.96M |
| June 30, 2018 | -12.94M |
| March 31, 2018 | -13.18M |
| December 31, 2017 | -10.96M |
| September 30, 2017 | -9.359M |
| June 30, 2017 | -10.25M |
| March 31, 2017 | -34.24M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.733M |
| Total Expenses (Quarterly) | 15.74M |
| EPS Diluted (Quarterly) | -0.076 |
| Enterprise Value | 351.84M |
| Gross Profit Margin (Quarterly) | 97.82% |
| Profit Margin (Quarterly) | -2.05K% |
| Earnings Yield | -10.67% |
| Normalized Earnings Yield | -3.095 |